MRD-positive AML Clinical Study

Summary

This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.

Eligibility

Inclusion Criteria:

* AML (non-M3) compliant with WHO (2016) standards;
* In morphological complete remission.
* Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive.
* Age over 14 years old, male or female. Informed consent must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, informed consent must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family.

Exclusion Criteria:

* Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks
* The diagnosis is APL
* Those who were not considered suitable for inclusion by the researchers.

Conditions2

Interventions10

Related trials

• A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany — Blueprint Medicines Corporation
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. — Centre Leon Berard
• Avapritinib Rollover Study — Blueprint Medicines Corporation
• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML — Children's Hospital of Soochow University
• Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation — Children's Hospital of Soochow University
• Avapritinib With Decitabine in Patients With SM-AHN — H. Lee Moffitt Cancer Center and Research Institute
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — M.D. Anderson Cancer Center
• A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. — Ascentage Pharma Group Inc.

Browse More Trials